Home/Pipeline/PRECISE RCT

PRECISE RCT

Randomized outcomes evidence

CompletedResults 2022NCT03782688

Key Facts

Indication
Randomized outcomes evidence
Phase
Completed
Status
Results 2022
Company

About HeartFlow

HeartFlow's mission is to transform coronary artery disease from a leading cause of death into a proactively managed chronic condition. The company has achieved remarkable commercial success, with its technology deployed in over 1,800 institutions, used on 600,000+ patients, and secured near-universal U.S. insurance reimbursement. Its strategy centers on expanding its AI-powered platform from a diagnostic tool into a comprehensive, longitudinal management system for CAD, leveraging a vast and growing clinical evidence base.

View full company profile